$FBLGJun 3, 2026, 10:46 AMAI processed
FBLG doses first patients in Phase 1/2 diabetic foot ulcer trial
AI Summary
FibroBiologics said it has enrolled and dosed the first patients in its Phase 1/2 trial of CYWC628, an investigational topical allogeneic fibroblast‑spheroid therapy for diabetic foot ulcers. The randomized, multicenter Australian study will enroll up to 120 patients comparing standard of care (SoC) alone versus SoC plus low or high dose CYWC628, with an interim analysis after six weeks and interim data expected in Q3 2026 (primary results by end of 2026); the company recently raised $3M.
Positives
- First patient dosing completed in a Phase 1/2 trial for CYWC628
- Randomized, multicenter design with SoC control allows for comparative safety/efficacy readouts
- Interim analysis planned after six weeks with interim data expected in Q3 2026
Negatives
- Early-stage (Phase 1/2) trial — primary focus on safety and preliminary efficacy
- Company recently raised only $3M, suggesting limited near-term cash runway
- Shares trading near 52-week low, indicating market skepticism or weak liquidity